- Home
- AEYE vs RFL Comparison
AEYE vs RFL Comparison
Compare AEYE & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEYE | RFL |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Real Estate |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.9M | 61.1M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AEYE | RFL |
|---|---|---|
| Price | $5.95 | $1.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.63 | N/A |
| AVG Volume (30 Days) | ★ 204.3K | 103.5K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.56 | 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $40,311,000.00 | $917,000.00 |
| Revenue This Year | $13.50 | N/A |
| Revenue Next Year | $13.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 14.52 | ★ 43.96 |
| 52 Week Low | $5.50 | $1.12 |
| 52 Week High | $16.39 | $3.19 |
Technical Indicators
Market Signals| Indicator | AEYE | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 52.39 |
| Support Level | N/A | $1.35 |
| Resistance Level | $12.97 | $1.38 |
| Average True Range (ATR) | 0.59 | 0.12 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 11.41 | 32.73 |
Price Performance
Historical ComparisonAbout AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.